Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)

University of Colorado Denver (CU Denver)

Status and phase

Completed

Phase 2

Conditions

Metastatic PNET

High Risk Supratentorial PNET

Metastatic Medulloblastoma

Treatments

Drug: Carboplatin

Radiation: 24 Gy

Drug: Vincristine

Study type

Interventional

Funder types

Other

Identifiers

NCT01542736

06-1151

Details and patient eligibility

About

The purpose of this study is to study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.

Enrollment

8 patients

Sex

All

Ages

3 to 25 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age greater than 3 years and less than 25 years
Patients with classic histology or desmoplastic histology metastatic medulloblastoma by histological diagnosis and by head and spine MRI.
Patients with high-risk supratentorial, non-metastatic, PNET
Patients with metastatic PNET
Newly diagnosed patients who have not received prior therapy, with the exception of one short course of emergent chemotherapy in newly presenting patients with neurological compromise per provider decision
Only patients who are expected to survive at least 6 weeks will be eligible for this study.

Exclusion criteria